Market Research Logo

Alzheimer's Disease Global Clinical Trials Review, H1, 2017

Alzheimer's Disease Global Clinical Trials Review, H1, 2017

Summary

GlobalData's clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H1, 2017 provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • Clinical Trials by Region
    • Table figure 1: Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2017*
    • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2017*
    • Clinical Trials and Average Enrollment by Country
      • Table figure 2: Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
      • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
      • Table figure 3: Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
      • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table figure 4: Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table figure 5: Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
      • Top Countries Contributing to Clinical Trials in North America
        • Table figure 6: Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2017*
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
        • Table figure 7: Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
      • Top Five Countries Contributing to Clinical Trials in Central and South America
        • Table figure 8: Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
        • Table Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
  • Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
    • Table figure 9: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017*
    • Table Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017*
  • Clinical Trials by Phase in G7 Countries
    • Table figure 10: Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
    • Table Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Clinical Trials in G7 Countries by Trial Status
    • Table figure 11: Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
    • Table Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials
    • Table figure 12: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017*
    • Table Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017*
  • Clinical Trials by Phase in E7 Countries
    • Table figure 13: Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
    • Table Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Clinical Trials in E7 Countries by Trial Status
    • Table figure 14: Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
    • Table Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Clinical Trials by Phase
    • Table figure 15: Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2017*
    • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2017*
    • In Progress Trials by Phase
      • Table figure 16: Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
      • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Clinical Trials by Trial Status
    • Table figure 17: Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017*
    • Table Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Clinical Trials by End Point Status
    • Table figure 18: Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017*
    • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Subjects Recruited Over a Period of Time
    • Table figure 19: Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
    • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Clinical Trials by Sponsor Type
    • Table figure 20: Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
    • Table Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Prominent Sponsors
    • Table figure 21: Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
    • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
    • Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials
      • Table figure 22: Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
      • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Prominent Drugs
    • Table figure 23: Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
    • Table Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • Latest Clinical Trials News on Alzheimer's Disease
    • Mar 20, 2017: Corium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex Donepezil Patch
    • Mar 16, 2017: QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference
    • Mar 15, 2017: Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer's Disease
    • Mar 10, 2017: Nature Cell Started Commercial Clinical Trials Phase I and II `ASTROSTEM,' Stem Cell Drug for Alzheimers Disease Treatment in US
    • Mar 08, 2017: TGA Regulatory Approval Received for Alzheimer's Phase II Trial
    • Mar 08, 2017: Diabetes drug shows promise for safely treating, detecting Alzheimers disease
    • Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease
    • Mar 06, 2017: BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
    • Mar 06, 2017: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease
    • Mar 01, 2017: Luye Pharma Group: Announcement Approval To Commence Clinical Trials For Rivastigmine Multi-Day Transdermal Patch In Germany
    • Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer's Therapy Crenezumab
    • Feb 28, 2017: Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer's
    • Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease
    • Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy
    • Feb 14, 2017: Cantabio Pharmaceuticals to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimers Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease
    • Feb 13, 2017: Alzheon to Present New Clinical Data and Analyses for ALZ-801 and Its Active Molecule Tramiprosate at the 13th International Conference on Alzheimer's and Parkinson's Diseases
    • Feb 09, 2017: Xanamem research published in prestigious medical journal
    • Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment
    • Jan 26, 2017: New drug SAK3 may offer hope to Alzheimer's disease patients
    • Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria
    • Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy
    • Jan 25, 2017: Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience
    • Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board
    • Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial – XanADu
    • Jan 09, 2017: Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients
    • Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer's Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers
    • Jan 03, 2017: FDA Approval to Commence Alzheimers Disease Clinical Trial
    • Dec 27, 2016: Investigational new drug for Alzheimer's scheduled for first study in humans
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report